2025
The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study
Huelsboemer L, Hosseini H, Klimitz F, Diatta F, Boroumand S, O'Brien C, Parikh N, Stögner V, Formica R, Ko C, Azzi J, Draper E, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study. Journal Of Plastic Reconstructive & Aesthetic Surgery 2025, 103: 286-296. PMID: 40043533, DOI: 10.1016/j.bjps.2025.01.028.Peer-Reviewed Original ResearchDe novo donor-specific antibodiesDonor-specific antibodiesDonor-specific antibody positivityChronic rejectionC4d depositionGraft lossPrognostic relevanceRejection gradeGrades of acute cellular rejectionDonor-specific antibody statusOccurrence of chronic rejectionTime pointsFacial vascularized composite allotransplantationAcute rejection gradeAcute cellular rejectionTissue typing laboratoriesAcute rejection eventsRetrospective cohort studyTransplant-related outcomesFace transplant patientsVascularized composite allotransplantationCellular rejectionTransplant patientsC4d levelsRetrospective analysisB-cell infiltration distinguishes mucosal from skin patterns of rejection in facial vascularized composite allografts
Kauke-Navarro M, Crisler W, Younis N, Khetani R, Sadigh S, Teague J, Ho Sui S, Ko C, Zhan Q, Steuart S, Treister N, Pober J, Azzi J, Clark R, Pomahac B. B-cell infiltration distinguishes mucosal from skin patterns of rejection in facial vascularized composite allografts. American Journal Of Transplantation 2025 PMID: 39842779, DOI: 10.1016/j.ajt.2025.01.013.Peer-Reviewed Original ResearchFacial vascularized composite allotransplantationPeripheral blood mononuclear cellsB cell infiltrationB cellsMucosal rejectionRejection monitoringFacial vascularized composite allograftT cell-mediated rejectionSigns of immune activationNon-rejection biopsiesGranzyme B expressionB cell populationsInnate-like B cellsBlood mononuclear cellsVascularized composite allograftsVascularized composite allotransplantationAcute rejectionOral mucosaT cellsPattern of rejectionImmune activationMucosal biopsiesPlasma cellsSkin biopsiesMononuclear cells
2024
The role of C4d and donor specific antibodies in face and hand transplantation—a systematic review
Huelsboemer L, Moscarelli J, Dony A, Boroumand S, Kochen A, Knoedler L, Yu C, Hauc S, Stögner V, Formica R, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The role of C4d and donor specific antibodies in face and hand transplantation—a systematic review. Frontiers In Transplantation 2024, 3: 1442006. PMID: 39291278, PMCID: PMC11405992, DOI: 10.3389/frtra.2024.1442006.Peer-Reviewed Original ResearchDonor-specific antibodiesSerum donor-specific antibodiesAntibody-mediated rejectionHigher rejection gradesVascularized composite allotransplantationC4d depositionRejection gradeCellular rejectionRejection episodesSpecific antibodiesDonor-specific antibody statusManagement of antibody-mediated rejectionFace transplantationAcute cellular rejectionAcute rejection episodesAssociated with high gradeTime of biopsyAntibody mediated rejectionFisher's exact testMann-Whitney U testSystematic review of electronic databasesMechanisms of rejectionSystematic reviewReview of electronic databasesC4d stainingEvolution of Vascularized Composite Allotransplantation
Huelsboemer L, Pomahac B. Evolution of Vascularized Composite Allotransplantation. 2024, 15-27. DOI: 10.1007/978-3-031-57132-9_3.Peer-Reviewed Original ResearchVascularized composite allotransplantationSolid organ transplantationProlongation of ischemia timeReconstruction of complex tissue defectsContext of vascularized composite allotransplantationDevelopment of non-toxicTolerogenic strategiesChronic rejectionImmunosuppressive medicationsTolerance inductionComplex tissue defectsPatient selectionIschemia timeC-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via subset-selective monocyte activation
Kiefer J, Zeller J, Schneider L, Thomé J, McFadyen J, Hoerbrand I, Lang F, Deiss E, Bogner B, Schaefer A, Chevalier N, Horner V, Kreuzaler S, Kneser U, Kauke-Navarro M, Braig D, Woollard K, Pomahac B, Peter K, Eisenhardt S. C-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via subset-selective monocyte activation. Journal Of Advanced Research 2024 PMID: 38992424, DOI: 10.1016/j.jare.2024.07.007.Peer-Reviewed Original ResearchAcute allograft rejectionC-reactive proteinVascularized composite allotransplantationAllograft rejectionAcute rejectionAllograft survivalGraft rejectionAttenuate acute allograft rejectionPreventing acute allograft rejectionImmune responseLong-term allograft survivalFacial vascularized composite allotransplantationClinical allograft rejectionReduced allograft survivalChronic allograft rejectionIntravital imagingNon-classical monocytesMarkers of inflammationAcute-phase reactantsImmune-inflammatory reactionPro-inflammatory propertiesMononuclear phagocyte systemAcute-phase responseGraft infiltrationInnate immune responseImmune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchConceptsRegulatory myeloid cellsSolid organ transplantationVascularized composite allotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejectionLymphadenopathy and lymph node rejection following facial vascularized composite allotransplantation
Kauke-Navarro M, Sadigh S, Lee C, Panayi A, Knoedler L, Knoedler S, Stoegner V, Huelsboemer L, Jamil A, Ko C, Lian C, Murphy G, Pomahac B. Lymphadenopathy and lymph node rejection following facial vascularized composite allotransplantation. Journal Of Plastic Reconstructive & Aesthetic Surgery 2024, 91: 268-275. PMID: 38430863, DOI: 10.1016/j.bjps.2024.02.024.Peer-Reviewed Original ResearchLymph nodesVascularized composite allograftsGranzyme BDonor-derived immune cellsFacial vascularized composite allograftMedian time of presentationFacial vascularized composite allotransplantationImmunological processesGranzyme B expressionCytotoxic T cellsNecrotizing histiocytic lymphadenitisHead and neckRetrospective cohort studyTime of presentationStages of follow-upCoexistence of donorFace transplant patientsBilateral adenopathyIncreased histiocytesSuperficial lymph nodesVascularized composite allotransplantationBilateral lymphadenopathyAllograft rejectionTransplant patientsDendritic cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply